

## **FDA-GDUFA Reauthorization Stakeholder Meeting**

**April 12, 2016, 10:00 am - 11:00 pm**

**FDA White Oak Campus, Silver Spring, MD**

**Building 52/72, Conference Room 4100**

---

### **Purpose**

The Generic Drug User Fee Amendments of 2012 (GDUFA) requires that FDA hold monthly discussions with representatives of patient and consumer advocacy groups on their views on the reauthorization of GDUFA and their suggestions for changes to the GDUFA program. These discussions are to take place at least once every month during the GDUFA reauthorization negotiations between FDA and the generic drug industry.

### **Participants**

#### FDA

Mary Beth Clarke	CDER
Keith Flanagan	CDER
Michael Jones	CDER
Martha Nguyen	CDER

#### Stakeholders

Paul Brown	National Center for Health Research
Andrea Lowe	Society for Women's Health Research
Sarah Sorscher	Public Citizen

#### FDA Supporting Staff

Derek Griffing, Katie Stronati

### **Welcome and Overview**

Following introductions, FDA gave an overview of the progress of the GDUFA negotiation meetings.

### **Summary of Recent Negotiation Sessions**

FDA provided an overview of the GDUFA negotiation meetings between FDA and Industry held on March 30, March 31, April 5, and April 6, 2016. FDA explained that the first three meetings were generally focused on metric review goals and/or program enhancements for submissions in GDUFA II, including Abbreviated New Drug Applications (ANDAs), Prior Approval Supplements (PASs), and Drug Master Files (DMFs). FDA stated that the last meeting (April 6 session) continued discussions on the development of a pre-ANDA process in GDUFA II. FDA explained that a robust pre-ANDA process could include the following: controlled correspondence, product-specific guidance, and pre-ANDA meetings.

FDA encouraged stakeholders' participation at the May 20, 2016, GDUFA Regulatory Science Initiatives Public Hearing. FDA also encouraged stakeholders to visit [www.regulations.gov](http://www.regulations.gov) and submit their suggestions on topics for discussion at future stakeholder meetings to the following docket number: FDA-2012-N-0882.

### **Next Meeting**

The next stakeholder meeting is planned for Thursday, May 12, 2016.